162 related articles for article (PubMed ID: 21187510)
1. Pemetrexed-induced eyelid edema: incidence and clinical manifestations.
Schallier D; Decoster L; Fontaine C; De Grève J
Anticancer Res; 2010 Dec; 30(12):5185-8. PubMed ID: 21187510
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-induced edema of the eyelid.
Kurata T; Tamura K; Okamoto I; Satoh T; Nakagawa K; Fukuoka M
Lung Cancer; 2006 Nov; 54(2):241-2. PubMed ID: 16996165
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
Okamoto I; Takeda K; Daga H; Miyazaki M; Yonesaka K; Kiyota H; Tsurutani J; Ueda S; Ichikawa Y; Takeda M; Sekiguchi R; Tominaga K; Enatsu S; Nambu Y; Nakagawa K
Lung Cancer; 2010 Nov; 70(2):168-73. PubMed ID: 20236726
[TBL] [Abstract][Full Text] [Related]
4. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-induced eyelid edema in lung cancer.
Martins-Filho PR; Kameo SY; Mascarenhas-Oliveira AC; Vieira NF; Azevedo E
J Craniofac Surg; 2013 Jul; 24(4):e401-3. PubMed ID: 23851735
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer.
Kim HS; Lee GW; Kim JH; Kim HY; Kwon JH; Song HH; Kim HJ; Jung JY; Jang G; Choi DR; Park SM; Shin TR; Lee HS; Zang DY
Lung Cancer; 2010 Oct; 70(1):71-6. PubMed ID: 20096475
[TBL] [Abstract][Full Text] [Related]
7. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
Li L; Razak AR; Hughes A
Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
11. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Ferraldeschi R; Thatcher N; Lorigan P
Expert Rev Anticancer Ther; 2007 May; 7(5):635-40. PubMed ID: 17492928
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed-induced edema of the eyelid.
Guhl G; Diaz-Ley B; Sanchez-Perez J; Jimenez U; Garcia-Diez A
Lung Cancer; 2010 Aug; 69(2):249-50. PubMed ID: 20488577
[No Abstract] [Full Text] [Related]
15. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
18. [Update of pemetrexed in thoracic oncology].
Brechot JM; Morère JF
Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.
Lopes G; Chopra A; Kukutschka J; Portillo P; Bharwani L; Chang A
Singapore Med J; 2011 Mar; 52(3):190-4. PubMed ID: 21451928
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]